Research Status and Application Prospect of Personalizing Pancreatic Cancer Organoids in The Era of Precision Medicine_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 LICheng ^1,2 , CHENYong-hua ² ,  MAIGang ³ ,  LIUXu-bao ²

1. Rehabilitation Medicine Center, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China;
2. Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu 610041, Sichuan Province, China;
3. Department of Hepatobiliary Surgery, The People's Hospital of Deyang City, Deyang 618400, Sichuan Province, China;

Corresponding author：

MAIGang, Email: maigang68@hotmail.com; LIUXu-bao, Email: xbliu@medmail.com.cn

Keywords：

Precision medicine; Pancreatic cancer; Organoid; 3D cell culture; Chemosensitivity

DOI：

10.7507/1007-9424.20160326

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize current patient-derived organoids as preclinical cancer models, and its potential clinical application prospects. Methods Current patient-derived organoids as preclinical cancer models were reviewed according to the results searched from PubMed database. In addition, how cancer-derived human tumor organoids of pancreatic cancer could facilitate the precision cancer medicine were discussed. Results The cancer-derived human tumor organoids show great promise as a tool for precision medicine of pancreatic cancer, with potential applications for oncogene modeling, gene discovery and chemosensitivity studies. Conclusion The cancer-derived human tumor organoids can be used as a tool for precision medicine of pancreatic cancer.

Citation： LI Cheng, CHEN Yong-hua, MAI Gang, LIU Xu-bao. Research Status and Application Prospect of Personalizing Pancreatic Cancer Organoids in The Era of Precision Medicine. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2016, 23(10): 1272-1275. doi: 10.7507/1007-9424.20160326 Copy

1.	Jameson JL, Longo DL. Precision medicine-personalized, problematic, and promising. N Engl J Med, 2015, 372(23):2229-2234.
2.	Phillips R. Innovation:organoids-a better model for prostate cancer. Nat Rev Urol, 2014, 11(11):604.
3.	Gao D, Chen Y. Organoid development in cancer genome discovery. Curr Opin Genet Dev, 2015, 30:42-48.
4.	Cantrell MA, Kuo CJ. Organoid modeling for cancer precision medicine. Genome Med, 2015, 7(1):32.
5.	Unger FT, Witte I, David KA. Prediction of individual response to anticancer therapy:historical and future perspectives. Cell Mol Life Sci, 2015, 72(4):729-757.
6.	Zhang HC, Kuo CJ. Personalizing pancreatic cancer organoids with hPSCs. Nat Med, 2015, 21(11):1249-1251.
7.	Knudsen ES, O'Reilly EM, Brody JR, et al. Genetic diversity of pancreatic ductal adenocarcinoma and opportunities for precision medicine. Gastroenterology, 2016, 150(1):48-63.
8.	Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med, 2015, 372(9):793-795.
9.	崔晓林. 中国将启动精准医疗计划2030年前投入600亿元"精准医学"会颠覆传统医疗产业吗? 中国经济周刊, 2015,39:34-36.
10.	张华. 精准医疗,医疗界新革命. 经营者. 2015, 6:285-286.
11.	王晓峰, 黄新余. 进展期胰腺癌的综合治疗进展. 中华内分泌外科杂志, 2010, 4(3):203-205.
12.	高军. 胰腺癌分子靶向治疗的现状及展望. 中华内分泌外科杂志, 2011, 5(1):57-59.
13.	Ravi M, Paramesh V, Kaviya SR, et al. 3D cell culture systems:advantages and applications. J Cell Physiol, 2015, 230(1):16-26.
14.	Xinaris C, Brizi V, Remuzzi G. Organoid models and applications in biomedical research. Nephron, 2015, 130(3):191-199.
15.	Kimlin L, Kassis J, Virador V. 3D in vitro tissue models and their potential for drug screening. Expert Opin Drug Discov, 2013, 8(12):1455-1466.
16.	Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell, 2014, 159(1):176-187.
17.	Xu X, Farach-Carson MC, Jia X. Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol Adv, 2014, 32(7):1256-1268.
18.	Vela I, Chen Y. Prostate cancer organoids:a potential new tool for testing drug sensitivity. Expert Rev Anticancer Ther, 2015, 15(3):261-263.
19.	Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell, 2015, 160(1-2):324-338.
20.	Patman G. Pancreatic cancer:From normal to metastases-a whole gamut of pancreatic organoids. Nat Rev Gastroenterol Hepatol, 2015, 12(2):61.
21.	Francies HE, Garnett MJ. What role could organoids play in the personalization of cancer treatment? Pharmacogenomics, 2015, 16(14):1523-1526.
22.	van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell, 2015, 161(4):933-945.
23.	Huang L, Holtzinger A, Jagan I, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med, 2015, 21(11):1364-1371.
24.	哈罗德·瓦穆斯, 张国锋, 马晋平. 精准医疗计划与癌症研究. 世界科学, 2015, 3:8-9.
25.	Unger C, Kramer N, Walzl A, et al. Modeling human carcinomas:physiologically relevant 3D models to improve anti-cancer drug development. Adv Drug Deliv Rev, 2014, 79-80:50-67.
26.	Schreiber-Brynzak E, Klapproth E, Unger C, et al. Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs. Invest New Drugs, 2015, 33(4):835-847.
27.	Coleman SJ, Watt J, Arumugam P, et al. Pancreatic cancer organotypics:High throughput, preclinical models for pharmacological agent evaluation. World J Gastroenterol, 2014, 20(26):8471-8481.
28.	Kenny HA, Lal-Nag M, White EA, et al. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun, 2015, 6:6220.
29.	Clevers H, Bender E. Q&A:Hans clevers. Banking on organoids. Nature, 2015, 521(7551):S15.
30.	Cirkel GA, Gadellaa-van Hooijdonk CG, Koudijs MJ, et al. Tumor heterogeneity and personalized cancer medicine:are we being outnumbered? Future Oncol, 2014, 10(3):417-428.
31.	Chantrill LA, Nagrial AM, Watson C, et al. Precision medicine for advanced pancreas cancer:the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clin Cancer Res, 2015, 21(9):2029-2037.
32.	Pauli C, Puca L, Emerling B, et al. Development of patient derived tumor organoids to guide precision medicine. Modern Pathol, 2016, 29:458A-459A.
33.	Baker LA, Tiriac H, Clevers H, Tuveson DA. Modeling Pancreatic Cancer with Organoids. Trends Cancer. 2016, 2(4):176-190.
34.	Astashkina A, Grainger DW. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. Adv Drug Deliv Rev, 2014, 69-70:1-18.
35.	Neal JT, Kuo CJ. Organoids as models for neoplastic transformation. Annu Rev Pathol, 2016, 11:199-220.

1. Jameson JL, Longo DL. Precision medicine-personalized, problematic, and promising. N Engl J Med, 2015, 372(23):2229-2234.
2. Phillips R. Innovation:organoids-a better model for prostate cancer. Nat Rev Urol, 2014, 11(11):604.
3. Gao D, Chen Y. Organoid development in cancer genome discovery. Curr Opin Genet Dev, 2015, 30:42-48.
4. Cantrell MA, Kuo CJ. Organoid modeling for cancer precision medicine. Genome Med, 2015, 7(1):32.
5. Unger FT, Witte I, David KA. Prediction of individual response to anticancer therapy:historical and future perspectives. Cell Mol Life Sci, 2015, 72(4):729-757.
6. Zhang HC, Kuo CJ. Personalizing pancreatic cancer organoids with hPSCs. Nat Med, 2015, 21(11):1249-1251.
7. Knudsen ES, O'Reilly EM, Brody JR, et al. Genetic diversity of pancreatic ductal adenocarcinoma and opportunities for precision medicine. Gastroenterology, 2016, 150(1):48-63.
8. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med, 2015, 372(9):793-795.
9. 崔晓林. 中国将启动精准医疗计划2030年前投入600亿元"精准医学"会颠覆传统医疗产业吗? 中国经济周刊, 2015,39:34-36.
10. 张华. 精准医疗,医疗界新革命. 经营者. 2015, 6:285-286.
11. 王晓峰, 黄新余. 进展期胰腺癌的综合治疗进展. 中华内分泌外科杂志, 2010, 4(3):203-205.
12. 高军. 胰腺癌分子靶向治疗的现状及展望. 中华内分泌外科杂志, 2011, 5(1):57-59.
13. Ravi M, Paramesh V, Kaviya SR, et al. 3D cell culture systems:advantages and applications. J Cell Physiol, 2015, 230(1):16-26.
14. Xinaris C, Brizi V, Remuzzi G. Organoid models and applications in biomedical research. Nephron, 2015, 130(3):191-199.
15. Kimlin L, Kassis J, Virador V. 3D in vitro tissue models and their potential for drug screening. Expert Opin Drug Discov, 2013, 8(12):1455-1466.
16. Gao D, Vela I, Sboner A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell, 2014, 159(1):176-187.
17. Xu X, Farach-Carson MC, Jia X. Three-dimensional in vitro tumor models for cancer research and drug evaluation. Biotechnol Adv, 2014, 32(7):1256-1268.
18. Vela I, Chen Y. Prostate cancer organoids:a potential new tool for testing drug sensitivity. Expert Rev Anticancer Ther, 2015, 15(3):261-263.
19. Boj SF, Hwang CI, Baker LA, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell, 2015, 160(1-2):324-338.
20. Patman G. Pancreatic cancer:From normal to metastases-a whole gamut of pancreatic organoids. Nat Rev Gastroenterol Hepatol, 2015, 12(2):61.
21. Francies HE, Garnett MJ. What role could organoids play in the personalization of cancer treatment? Pharmacogenomics, 2015, 16(14):1523-1526.
22. van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell, 2015, 161(4):933-945.
23. Huang L, Holtzinger A, Jagan I, et al. Ductal pancreatic cancer modeling and drug screening using human pluripotent stem cell- and patient-derived tumor organoids. Nat Med, 2015, 21(11):1364-1371.
24. 哈罗德·瓦穆斯, 张国锋, 马晋平. 精准医疗计划与癌症研究. 世界科学, 2015, 3:8-9.
25. Unger C, Kramer N, Walzl A, et al. Modeling human carcinomas:physiologically relevant 3D models to improve anti-cancer drug development. Adv Drug Deliv Rev, 2014, 79-80:50-67.
26. Schreiber-Brynzak E, Klapproth E, Unger C, et al. Three-dimensional and co-culture models for preclinical evaluation of metal-based anticancer drugs. Invest New Drugs, 2015, 33(4):835-847.
27. Coleman SJ, Watt J, Arumugam P, et al. Pancreatic cancer organotypics:High throughput, preclinical models for pharmacological agent evaluation. World J Gastroenterol, 2014, 20(26):8471-8481.
28. Kenny HA, Lal-Nag M, White EA, et al. Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy. Nat Commun, 2015, 6:6220.
29. Clevers H, Bender E. Q&A:Hans clevers. Banking on organoids. Nature, 2015, 521(7551):S15.
30. Cirkel GA, Gadellaa-van Hooijdonk CG, Koudijs MJ, et al. Tumor heterogeneity and personalized cancer medicine:are we being outnumbered? Future Oncol, 2014, 10(3):417-428.
31. Chantrill LA, Nagrial AM, Watson C, et al. Precision medicine for advanced pancreas cancer:the individualized molecular pancreatic cancer therapy (IMPaCT) trial. Clin Cancer Res, 2015, 21(9):2029-2037.
32. Pauli C, Puca L, Emerling B, et al. Development of patient derived tumor organoids to guide precision medicine. Modern Pathol, 2016, 29:458A-459A.
33. Baker LA, Tiriac H, Clevers H, Tuveson DA. Modeling Pancreatic Cancer with Organoids. Trends Cancer. 2016, 2(4):176-190.
34. Astashkina A, Grainger DW. Critical analysis of 3-D organoid in vitro cell culture models for high-throughput drug candidate toxicity assessments. Adv Drug Deliv Rev, 2014, 69-70:1-18.
35. Neal JT, Kuo CJ. Organoids as models for neoplastic transformation. Annu Rev Pathol, 2016, 11:199-220.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Research Status and Application Prospect of Personalizing Pancreatic Cancer Organoids in The Era of Precision Medicine

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content